LSV Asset Management grew its holdings in GlaxoSmithKline plc (NYSE:GSK) by 30.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 470,900 shares of the pharmaceutical company’s stock after buying an additional 109,500 shares during the quarter. LSV Asset Management’s holdings in GlaxoSmithKline were worth $16,702,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in GSK. Gotham Asset Management LLC lifted its holdings in GlaxoSmithKline by 4.3% in the 2nd quarter. Gotham Asset Management LLC now owns 26,495 shares of the pharmaceutical company’s stock worth $1,142,000 after buying an additional 1,103 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in GlaxoSmithKline by 18.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,960 shares of the pharmaceutical company’s stock worth $818,000 after buying an additional 2,968 shares during the period. Americafirst Capital Management LLC purchased a new stake in GlaxoSmithKline in the 2nd quarter worth approximately $299,000. Nomura Holdings Inc. purchased a new stake in GlaxoSmithKline in the 2nd quarter worth approximately $265,000. Finally, Verition Fund Management LLC purchased a new stake in GlaxoSmithKline in the 2nd quarter worth approximately $1,300,000. Institutional investors and hedge funds own 9.66% of the company’s stock.
GSK has been the subject of several research analyst reports. Zacks Investment Research upgraded GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a report on Wednesday, October 18th. UBS Group upgraded GlaxoSmithKline from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $35.04 to $35.85 in a report on Monday, November 27th. TheStreet upgraded GlaxoSmithKline from a “c+” rating to a “b” rating in a report on Wednesday, October 25th. Barclays upgraded GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 16th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a report on Tuesday, October 24th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $38.57.
GlaxoSmithKline (NYSE:GSK) last released its earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 EPS for the quarter, beating the Zacks’ consensus estimate of $0.69 by $0.03. The company had revenue of $10.14 billion during the quarter, compared to analysts’ expectations of $9.89 billion. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. analysts expect that GlaxoSmithKline plc will post 2.8 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, April 12th. Stockholders of record on Friday, February 23rd will be paid a $0.633 dividend. This represents a $2.53 dividend on an annualized basis and a dividend yield of 6.94%. The ex-dividend date is Thursday, February 22nd. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.50. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 258.23%.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/02/10/lsv-asset-management-buys-109500-shares-of-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.